These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. Kwon J, Kim IH, Kim BH, Kim TM, Heo DS. Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):91-8. PubMed ID: 25721091 [Abstract] [Full Text] [Related]
23. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M. Srp Arh Celok Lek; 1998 May 01; 126(9-10):345-8. PubMed ID: 9863405 [Abstract] [Full Text] [Related]
25. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST. Ann Hematol; 2011 Jul 01; 90(7):809-18. PubMed ID: 21229246 [Abstract] [Full Text] [Related]
30. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Sohn BS, Kim SM, Yoon DH, Kim S, Lee DH, Kim JH, Lee SW, Huh J, Suh C. Ann Hematol; 2012 Nov 01; 91(11):1731-9. PubMed ID: 22752193 [Abstract] [Full Text] [Related]
31. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP. J Clin Oncol; 2011 Feb 20; 29(6):690-7. PubMed ID: 21189393 [Abstract] [Full Text] [Related]
33. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma]. Yang BY, Yong WB, Zhu J, Zheng W, Zhang YT, Wang XP, Meng SN. Zhonghua Zhong Liu Za Zhi; 2005 Mar 20; 27(3):174-6. PubMed ID: 15946571 [Abstract] [Full Text] [Related]
35. [Clinical and pathological analysis of 15 cases with primary breast lymphoma]. Huang DZ, He XH, Yang S, Shi YK. Ai Zheng; 2004 Aug 20; 23(8):939-42. PubMed ID: 15301719 [Abstract] [Full Text] [Related]
36. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Ann Rheum Dis; 2006 Aug 20; 65(8):1033-7. PubMed ID: 16322082 [Abstract] [Full Text] [Related]
39. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD. Cancer; 2001 Jun 15; 91(12):2440-6. PubMed ID: 11413536 [Abstract] [Full Text] [Related]
40. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Hausdorff J, Davis E, Long G, Hoppe R, van der Pas M, Lassman C, Kamel O, Jacobs C. Cancer J Sci Am; 1997 Jun 15; 3(5):303-11. PubMed ID: 9327155 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]